Amgen speaks out about bone density concerns with obesity drug

By Yahoo! Finance | Nov 14, 2024 at 08:37 AM EST

Amgen responded to concerns over bone density loss in its obesity drug candidate, MariTide, following an analyst's comments that caused a market drop. The company stated no association with BMD changes and is set to release Phase II data soon.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.